Stocks Gilead Sciences Inc


  • Jan 5- Gilead Sciences Inc said its experimental hepatitis B drug was found safer than but as effective as its approved treatment, Viread, in two late-stage studies. Gilead's shares rose 1 percent to $99 in premarket trading. The company plans to seek regulatory approval for TAF in the United States and Europe in the first quarter of 2016..

  • Gilead's hep B drug succeeds in late-stage trials Tuesday, 5 Jan 2016 | 8:53 AM ET

    Jan 5- Gilead Sciences Inc said its once-daily experimental hepatitis B drug was found to be as effective as its approved drug, Viread, in two late-stage studies. The drug, tenofovir alafenamide, or TAF, also showed improved renal and bone safety compared with Viread, Gilead said on Tuesday. Gilead plans to submit regulatory applications for TAF in the United...

  • These are the biotech stocks to own next year: Pro Sunday, 3 Jan 2016 | 2:00 PM ET

    RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.

  • 10 biotech analysts that can make you money Thursday, 31 Dec 2015 | 6:00 AM ET

    Uri Gruenbaum, CEO of TipRanks, listed the top 10 biotech analysts on Wall Street based on the returns they've generated since 2009.

  • Street: Volatile year ahead, keep picking stocks Monday, 28 Dec 2015 | 12:38 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Stock picking will once again rule in 2016, according to strategists on Wall Street. Here are 10 names to consider.

  • Cramer Remix—One of the few doing everything right Wednesday, 23 Dec 2015 | 7:03 PM ET
    Jim Cramer on "Mad Money"

    “Mad Money” host Jim Cramer is telling investors which stock is headed higher for the long-term.

  • Cramer: Biotechs to load up on for 2016 Wednesday, 23 Dec 2015 | 6:48 PM ET
    Biotech research

    Jim Cramer prepares investors for the biotech group to come roaring back in 2016, and shares his top picks.

  • What's behind skyrocketing drug prices Monday, 21 Dec 2015 | 1:37 PM ET
    Martin Shkreli.

    The latest drug-price increases are just the tip of the iceberg, explains former Medtronic CEO Bill George.

  • Big U.S. pharmacies square off on Daraprim supplies Friday, 18 Dec 2015 | 1:00 AM ET

    Dec 18- As Turing Pharmaceuticals Chief Executive Officer Martin Shkreli contends with charges of securities fraud, major U.S. pharmacies are moving to assure patients of continued access to the company's key drug, Daraprim. CVS Health Corp, the No. 2 U.S. drug benefit manager, told Reuters on Thursday it can provide an alternative to Daraprim that is compounded...

  • Dec 17- The U.S. Food and Drug Administration has postponed by three months its decision on Intercept Pharmaceuticals Inc's marketing application for its lead drug, to treat a kind of liver disease. Intercept said the FDA would now announce its decision on May 29 as it required more time to analyze additional clinical data submitted by the company.

  • Drug pricing has become a contentious issue among drugmakers and lawmakers in the United States, with companies like Valeant Pharmaceuticals and Turing Pharmaceuticals facing a backlash for sharply hiking prices of older drugs they have bought cheaply. Pharnext thinks it can sell its promising drug- a combination of three already-approved drugs- for...

  • *Yellen gives Congress upbeat view on march towards liftoff. Dec 3- U.S. stocks were sharply lower on Thursday as European Central Bank's minimal rate cut and extended stimulus failed to impress investors, and Federal Reserve Chair Janet Yellen's comments hardened expectations of an interest rate hike this month. European shares suffered their biggest fall...

  • Shares of medtech companies such as Edwards Lifesciences, Boston Scientific and Becton Dickinson have outperformed the broad healthcare sector, and especially pharmaceutical and biotech shares, over the past two months since U.S. presidential candidate Hillary Clinton tweeted she planned to address specialty drug "price gouging." He said he likes...

  • More innovative companies aren't just tech giants Wednesday, 2 Dec 2015 | 10:44 AM ET
    A scientist at Gilead Sciences analyzes patient antibody levels at the Gilead laboratory in Foster City, Calif.

    Roughly two-thirds of the top 50 innovative companies are not squarely in technology, according to a ranking by The Boston Consulting Group.

  • Behind the tricky balance of drug price and supply Wednesday, 2 Dec 2015 | 10:25 AM ET

    The national conversation on drug prices is getting louder, and patients increasingly want a voice in that discussion.

  • 5 stocks likely to boost their dividends Tuesday, 1 Dec 2015 | 6:43 PM ET
    A television host points to a graph on a screen at the New York Stock Exchange in New York.

    This dividend health rating system predicts which dividends are likely to rise or fall. Which stocks made the cut?

  • Chart analyst: This group is poised to rally Friday, 27 Nov 2015 | 11:03 AM ET
    Trader on the floor of the New York Stock Exchange.

    Mark Newton, chief technical analyst at Greywolf Execution Partners, shares his top investment idea for the months ahead.

  • Will rate hike ruin Santa Claus rally?: Insana Tuesday, 24 Nov 2015 | 9:37 AM ET
    Santa Claus waves to the crowd during the Macy's Thanksgiving Day Parade on November 27, 2014 in New York City.

    Here's how the Fed could play Grinch and wreck the Santa Claus rally, says Ron Insana.

  • Lightning Round: Most hated stock in the universe Tuesday, 17 Nov 2015 | 7:00 PM ET
    Mad Money Lightning Round

    Jim Cramer gives his opinion on various caller favorite stocks, including this hated biotech play.

  • Nov 17- The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective. The United States and New Zealand are the only two countries that allow direct-to-consumer advertising...